Lenalidomide for Treatment of Myelodysplastic Syndromes

Author(s): Rami S. Komrokji, Alan F. List

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 22 , 2012

Become EABM
Become Reviewer
Call for Editor


Lenalidomide is a second generation immunomodulatory agent (IMiD), which currently represents the standard of care for treatment of transfusion dependent lower risk myelodysplastic syndrome (MDS) patients with deletion (5q). Lenalidomide has unique activity with a high transfusion independence rate observed in this subset of patients. In this article we summarize the clinical experience using lenalidomide for treatment of del (5q) MDS. We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS.

Keywords: Lenalidomide, myelodysplastic syndromes, deletion 5q, non-del(5q), immunomodulatory agent (IMiD), bone marrow failure, anemia, cytokines, apoptosis, myeloblast

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 01 June, 2012
Page: [3198 - 3203]
Pages: 6
DOI: 10.2174/1381612811209023198
Price: $65

Article Metrics

PDF: 13